Introduction {#S1}
============

Proctitis after prostate cancer radiation therapy is a primary determinant of quality of life (QOL) and remains an ongoing clinical challenge. Acute radiation proctitis commonly peaks during conventionally fractionated treatment ([@B1]--[@B4]) and resolves a few weeks to months after the completion of therapy ([@B5], [@B6]). Patients with acute radiation proctitis describe symptoms of bowel frequency and urgency, rectal pain, or rectal bleeding ([@B7]). Four to 50% of patients treated with conventionally fractionated intensity-modulated radiation therapy (IMRT) develop grade 2 or greater acute proctitis ([@B8]--[@B11]). The risk of acute radiation proctitis is dependent upon the rectal volume exposed to a high radiation dose ([@B12], [@B13]) as well as the fractionation schema ([@B14]). In an attempt to reduce radiation related bowel morbidity, pretreatment dietary intervention ([@B15]) or enemas ([@B16]) have been utilized with only modest improvements. Several studies have demonstrated that acute rectal symptoms may also be the best predictor of late proctitis ([@B17]--[@B19]).

Patient-reported outcomes have become an increasingly reliable tool when comparing the relative morbidity of the different treatment options for localized prostate cancer ([@B5]). In such a situation, it is important to select the most appropriate time point and recall period for symptom assessment as these time points will vary depending on the evaluated symptom and its acute or chronic nature. Not surprisingly, the rate of memory decay is impacted by the severity and temporal pattern of the symptom, with recall of mild and transient symptoms decaying faster than those of severe and persistent symptoms ([@B20]). Thus, assessment of toxicities too far after their occurrence may result in underestimation of their overall incidence in a given treatment group, and the differences between treatment groups may therefore be artificially minimized ([@B20]). An early time point with a short recall period, therefore, is generally preferable for acute and transient symptoms such as acute radiation proctitis ([@B21]).

Early results suggest that prostate SBRT with 35--40 Gy in four to five fractions confers rates of biochemical relapse-free survival and late rectal toxicity which are comparable to alternative radiation modalities ([@B22]--[@B24]). However, little data exist on acute bowel morbidity prior to the 1-month interval, creating a potential for recall bias in patient-reported outcomes. The goal of this study is to accurately delineate the acute rectal morbidity of this treatment modality in the setting of clinically localized prostate cancer.

Materials and Methods {#S2}
=====================

Patient Selection and Characteristics {#S2-1}
-------------------------------------

Patients eligible for study inclusion had clinically localized prostate cancer treated on a prospectively conducted IRB-approved institutional QOL protocol (IRB 12-1175). Risk groups were defined using the D'Amico criteria. Other patient and treatment characteristics, such as age, race, Charlson Comorbidity Index (CCI), prostate volume, pretreatment PSA, T stage, Gleason score, hormone treatment, use of anticoagulants and/or antiplatelets, and dose, were acquired from the medical records. Baseline QOL was assessed using the EQ-5D, which contains five general health questions (EQ-5D index) and a visual analog scale (EQ VAS), with higher values indicating better QOL ([@B25]).

SBRT Treatment Planning and Delivery {#S2-2}
------------------------------------

The CyberKnife robotic radiosurgical system (Accuray Inc., Sunnyvale, CA, USA) was used to deliver SBRT treatments ([@B26]). One week prior to simulation, gold fiducial markers were placed within the prostate under ultrasound guidance. For treatment planning, thin cut (1.25 mm) CT images as well as high-resolution magnetic resonance images were acquired and fused. The clinical target volume (CTV) encompassed the prostate and proximal seminal vesicles. The planning target volume (PTV) included a 3 mm (inferior, superior, and posterior) or 5 mm (anterior and lateral) expansion around the CTV. Pelvic lymph nodes were not treated. To account for interfraction and intrafraction prostate motion, fiducial-based tracking was used. Thirty-five or 36.25 Gy was delivered in five fractions (7--7.25 Gy per fraction) to the PTV. The rectum was contoured as a solid structure from the anus (at the level of the ischial tuberosities on axial CT images) to the rectosigmoid flexure. Dose-volume histogram (DVH) analysis was performed using Multiplan (Accuray Inc., Sunnyvale, CA, USA) inverse treatment planning. No more than 1 cc of rectal volume was to receive 36 Gy. Assuming an α/β of 3 Gy for late bowel complications, this is biologically equivalent to approximately 74 Gy administered in 2 Gy fractions. Other rectal DVH constraints included the following: \<50% rectal volume was to receive 50% of the prescribed dose, \<20% to receive 80% of the dose, \<10% to receive 90% of the dose, and \<5% to receive 100% of the dose. Typical dose distributions have been previously described ([@B27]). To optimize the prostate--rectal wall distance and to reduce intrafraction prostate motion, patients were instructed to adhere to a low-residual diet and undergo enemas prior to simulation and treatment delivery ([@B16]).

Follow-Up and Statistical Analysis {#S2-3}
----------------------------------

Physician-reported acute bowel toxicity was prospectively assessed at the initial and each subsequent follow-up visit. The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv.4) was used to assign toxicity scores. Acute toxicity was defined as having occurred up to 3 months following completion of prostate SBRT. Grade 1 was defined by the CTCAE criteria as rectal discomfort with intervention not indicated. Grade 2 was defined as symptoms (e.g., rectal discomfort, passing blood, or mucus), medical intervention indicated, limiting instrumental activities of daily living (ADL). In this study, patients were generally assigned a grade 2 for requiring a new medication (i.e., steroid suppository or anti-diarrheal). Grade 3 was defined as severe symptoms, fecal urgency, or stool incontinence, limiting self care ADL. In this study, patients were generally assigned grade 3 for requiring a surgical intervention. Cumulative likelihood estimates for acute ≥ grade 2 bowel toxicity were determined using the Kaplan--Meier method.

Acute proctitis was also prospectively reported by patients using the bowel domain of the Expanded Prostate Index Composite (EPIC)-26 questionnaire at baseline (1 hour prior to the first fraction) and at 1 week, 1 month, and 3 months following the final SBRT treatment ([@B28]). Patients completed a paper questionnaire at baseline, 1 month, and 3 months. However, to minimize the burden of frequent clinic visits, the 1 week questionnaire was completed *via* a nursing phone interview. The recall period, the time patients are asked to consider when answering questions, was 1 week at the 1 week time point and 1 month for all others. The EPIC-26 bowel domain includes five questions related to individual symptoms (questions 6a--e: urgency, frequency, pain, bloody stool, incontinence) and one question (question 7) related to overall bother (degree of annoyance caused by bowel symptoms).

The EPIC bowel domain and its encompassing questions are scored on a range from 0 to 100, with higher values representing more favorable bowel symptoms. For each EPIC question, the responses were grouped into three clinically relevant categories (no problem, very small to small problem, and moderate to big problem). To statistically compare changes between time points, the levels of responses were assigned a score. The significance of the mean changes in the scores was then assessed by using the Wilcoxon signed-rank test, generating two-sided *p* values. Clinically significant change was assessed by the minimally important difference (MID) in EPIC score, and this was defined as a change of 1/2 standard deviation (SD) from the baseline ([@B29]).

Results {#S3}
=======

From May 2013 to August 2014, 103 prostate cancer patients were treated on an institutional prospective SBRT QOL protocol. They were ethnically diverse, with 56.3% being of Caucasian ancestry. The median age was 69 years (range, 48--85 years) (Table [1](#T1){ref-type="table"}). By D'Amico classification, 19.4% patients were low risk, 65.0% intermediate risk, and 15.5% high risk. A small percentage of patients (16.5%) also underwent androgen deprivation therapy (ADT). Thirty-seven percent also utilized anticoagulants and/or antiplatelets. Approximately half (52%) of the patients were treated with 36.25 Gy in five 7.25 Gy fractions, and 48% were treated with 35 Gy in five 7 Gy fractions.

###### 

**Patient and treatment specifics**.

                                                              Patients *N* = 103 (%)   n
  ------------------------------------- --------------------- ------------------------ ----
  Age (years)                           Median 69 (48--85)                             
                                        \<60                  11.7                     12
                                        60--69                44.7                     46
                                        70--79                35.0                     36
                                        ≥80                   8.7                      9
  Race                                  White                 56.3                     58
                                        Black                 28.2                     29
                                        Other                 15.5                     16
  Charlson comorbidity index            CCI = 0               61.2                     63
                                        CCI = 1               30.1                     31
                                        CCI ≥ 2               8.7                      9
  Prostate volume (cc)                  Median 36 (13--125)                            
  Pre-txt PSA (ng/ml)                   Median 7 (2.2--50)                             
                                        ≤10                   75.7                     78
                                        \>10 and ≤20          16.5                     17
                                        \>20                  7.8                      8
  T stage                               T1c                   63.1                     65
                                        T2a                   20.4                     21
                                        T2b                   12.6                     13
                                        T2c                   2.9                      3
                                        T3                    1.0                      1
  Gleason score                         3 + 3 = 6             32.0                     33
                                        3 + 4 = 7             34.0                     35
                                        4 + 3 = 7             20.4                     21
                                        3 + 5 = 8             1.0                      1
                                        4 + 4 = 8             10.7                     11
                                        4 + 5 = 9             1.9                      2
  Risk groups (D'Amico)                 Low                   19.4                     20
                                        Intermediate          65.0                     67
                                        High                  15.5                     16
  Hormone treatment                     Yes                   16.5                     17
                                        No                    83.5                     86
  Use of anticoagulants/antiplatelets   Yes                   36.9                     38
                                        No                    63.1                     65
  Dose (Gy)                             35                    47.6                     49
                                        36.25                 52.4                     54

The prevalence of CTCAE-graded GI toxicities at each follow-up time point is illustrated in Table [2](#T2){ref-type="table"}, with individual symptoms as well as the highest GI toxicity per patient depicted independently. Bowel frequency and urgency was the most common toxicity, with 23% of patients experiencing grade 2 toxicity at seven days after treatment (Table [2](#T2){ref-type="table"}). The cumulative incidence of acute grade 2 GI toxicity was 23%. There were no acute grade 3 or greater toxicities.

###### 

**Prevalence of CTC graded gastrointestinal (GI) toxicities at each follow-up**.

  Follow-up time point      Day 7(%)   Month 1(%)   Month 3(%)   
  ------------------------- ---------- ------------ ------------ ----
  Bowel frequency/urgency   0          51           65           89
  1                         26         32           11           
  2                         23         3            0            
  Proctitis                 0          79           85           98
  1                         21         15           2            
  2                         0          0            0            
  Rectal bleeding           0          86           91           97
  1                         14         9            3            
  2                         0          0            0            
  Highest GI                0          43           54           84
  1                         34         43           16           
  2                         23         3            0            

Table [3](#T3){ref-type="table"} shows the baseline EQ-5D, EPIC bowel summary, and EPIC bowel bother scores. Table [4](#T4){ref-type="table"} shows mean changes in EPIC summary scores from baseline to 3 months of follow-up. A transient decline in the EPIC bowel summary score occurred at 1 week (mean change, −13.9; *p* \< 0.0001). However, the EPIC bowel summary score returned to baseline 3 months after SBRT (mean change from baseline, +0.03; *p* = 0.9370) (Table [4](#T4){ref-type="table"}). While bowel summary score declines at 1 week and 1 month were both statistically significant when compared to baseline (*p* \< 0.0001 for both), only the change at 1 week remained below the threshold for clinically significant change (MID = 6.5) (Figure [1](#F1){ref-type="fig"}). Table [3](#T3){ref-type="table"} shows that the mean baseline EPIC bowel bother score was 87.4. Bowel bother worsened after treatment, with a reduction in mean score to 63.5 at 1 week (mean change, −23.9; *p* \< 0.0001) (Table [4](#T4){ref-type="table"}). Bowel bother declines at 1 week and 1 month were statistically significant (*p* \< 0.0001 and *p* = 0.0002, respectively); however, only the change at 1 week met the threshold for clinically significant change (MID = 11.6) (Figure [2](#F2){ref-type="fig"}). The EPIC bowel bother score returned to near baseline at 3 months after SBRT (mean change from baseline, −1.8; *p* = 0.6567) (Table [4](#T4){ref-type="table"}).

###### 

**Pretreatment quality of life scores**.

                                Mean    SD      MID
  ----------------------------- ------- ------- -------
  **Baseline EQ-5D**                            
  EQ-5D index                   0.908   0.089   0.045
  EQ VAS                        80.2    14.87   7.4
  **Baseline EPIC-26 domain**                   
  Bowel summary                 92.6    12.99   6.5
  Bowel bother                  87.4    23.19   11.6

###### 

**Changes in EPIC bowel summary and overall bowel bother scores following SBRT for prostate cancer**.

  Domain          1-week post treatment (*n* = 102)   1-month post treatment (*n* = 100)   3-month post treatment (*n* = 82)                                                                                             
  --------------- ----------------------------------- ------------------------------------ ----------------------------------------------- ------ ------- ----------------------------------------------- ------- ------ --------------
  Bowel summary   −13.9                               12.99                                *p* \< 0.0001[\*](#tfn1){ref-type="table-fn"}   −4.5   13.18   *p* \< 0.0001[\*](#tfn1){ref-type="table-fn"}   +0.03   8.74   *p* = 0.9370
  Bowel bother    −23.9                               34.05                                *p* \< 0.0001[\*](#tfn1){ref-type="table-fn"}   −9.1   24.01   *p* = 0.0002[\*](#tfn1){ref-type="table-fn"}    −1.8    17.2   *p* = 0.6567

*\*Indicates statistical significance*.

![**Average EPIC bowel summary scores (baseline and following SBRT; question 6A-E of EPIC-26)**. Dashed lines represent the minimally important difference (MID) defined as the threshold for clinically significant change in scores (1/2 SD above and below the baseline). Higher EPIC score values (range 0--100) indicate a more satisfactory health-related QOL. Vertical lines at each time point represent 95% confidence interval.](fonc-06-00167-g001){#F1}

![**Overall bowel bother score (baseline and following SBRT; question 7 of EPIC-26)**. Dashed lines represent the minimally important difference (MID) defined as the threshold for clinically significant change in scores (1/2 SD above and below the baseline). Higher EPIC score values (range 0--100) indicate a more satisfactory health-related QOL. Vertical lines at each time point represent 95% confidence interval.](fonc-06-00167-g002){#F2}

Baseline moderate to big bowel symptoms including urgency, frequency, and incontinence were 4.9%, 3.9%, and 1.9%, respectively, with 1% experiencing bloody stool and 1.9% abdominal, pelvic, or rectal pain (Table [5](#T5){ref-type="table"}). All bowel symptoms increased at 1 week post-SBRT but returned to near baseline at 3 months (Table [5](#T5){ref-type="table"}). At baseline, 31% of patients reported some level of annoyance due to bowel symptoms, with 4.9% of patients feeling that bowel function was a moderate to big problem (Table [6](#T6){ref-type="table"}). This is consistent with other studies reporting baseline overall bowel problems in up to 3% of patients undergoing IMRT, proton therapy, or brachytherapy ([@B5], [@B30]). At 1 week following SBRT, 28% of patients felt that their bowel function was a moderate to big problem, and this number declined to 0% by 3 months. Radar plot distribution of individual bowel symptoms at baseline and following SBRT shows the majority of the patients experienced bowel urgency and frequency at 1 week after SBRT, and by 3 months all symptoms subsided to that of the baseline level (Figure [3](#F3){ref-type="fig"}).

###### 

**Patient-reported bowel symptoms after prostate SBRT as recorded by the EPIC-26 questions 6A (urgency to have a bowel movement), 6B (frequency of bowel movements), 6C (losing control of your stools), 6D (bloody stools), and 6E (abdominal, pelvic, or rectal pain)**.

                                            Start   Day 7                                      Month 1                                  Month 3
  ----------------------------------------- ------- ------------------------------------------ ---------------------------------------- ---------
  **Bowel urgency**                                                                                                                     
  No problem (%)                            71.8    52.0                                       56.0                                     65.5
  Very small-small problem (%)              23.3    22.5                                       40.0                                     29.9
  Moderate-big problem (%)                  4.9     25.5                                       4.0                                      4.6
  *p* Value                                         \<0.0001[\*](#tfn2){ref-type="table-fn"}   0.0056[\*](#tfn2){ref-type="table-fn"}   0.1128
  **Bowel frequency**                                                                                                                   
  No problem (%)                            78.6    55.9                                       59.0                                     79.3
  Very small-small problem (%)              17.5    19.6                                       37.0                                     19.5
  Moderate-big problem (%)                  3.9     24.5                                       4.0                                      1.1
  *p* Value                                         \<0.0001[\*](#tfn2){ref-type="table-fn"}   0.0015[\*](#tfn2){ref-type="table-fn"}   1.00
  **Incontinence**                                                                                                                      
  No problem (%)                            93.2    84.3                                       86.0                                     93.1
  Very small-small problem (%)              4.9     9.8                                        12.0                                     6.9
  Moderate-big problem (%)                  1.9     5.9                                        2.0                                      0.0
  *p* Value                                         0.0066[\*](#tfn2){ref-type="table-fn"}     0.1531                                   1.00
  **Bloody stools**                                                                                                                     
  No problem (%)                            94.2    86.3                                       89.0                                     94.3
  Very small-small problem (%)              4.9     8.8                                        10.0                                     4.6
  Moderate-big problem (%)                  1.0     4.9                                        1.0                                      1.0
  *p* Value                                         0.0182[\*](#tfn2){ref-type="table-fn"}     0.2439                                   0.8203
  **Pain (abdominal, pelvic, or rectal)**                                                                                               
  No problem (%)                            84.5    72.5                                       77.0                                     90.8
  Very small-small problem (%)              13.6    13.7                                       20.0                                     8.0
  Moderate-big problem (%)                  1.9     13.7                                       3.0                                      1.1
  *p* Value                                         0.0004[\*](#tfn2){ref-type="table-fn"}     0.0775                                   0.1294
  *N*                                       103     102                                        100                                      87

*\*Indicates statistical significance*.

###### 

**Patient-reported overall bowel bother after prostate SBRT as recorded by the EPIC-26 question 7**.

                                 Start   Day 7                                      Month 1                                  Month 3
  ------------------------------ ------- ------------------------------------------ ---------------------------------------- ---------
  **Bowel bother**                                                                                                           
  No problem (%)                 68.9    37.3                                       43.0                                     66.7
  Very small-small problem (%)   26.2    34.3                                       51.0                                     33.3
  Moderate-big problem (%)       4.9     28.4                                       6.0                                      0.0
  *p* Value                              \<0.0001[\*](#tfn3){ref-type="table-fn"}   0.0002[\*](#tfn3){ref-type="table-fn"}   0.6583
  *N*                            103     102                                        100                                      87

*\*Indicates statistical significance*.

![**Radar plots showing the distribution of individual bowel symptoms following SBRT for prostate cancer**. Higher EPIC score values (range 0--100) indicate a more satisfactory health-related QOL. Points farther out from the center indicate higher levels of bother with a given symptom.](fonc-06-00167-g003){#F3}

Discussion {#S4}
==========

What is the appropriate time point and recall period to assess acute bowel symptoms following prostate SBRT such that clinically meaningful symptoms are captured fully and accurately? Early results with prostate SBRT (35--40 Gy in four to five fractions) have suggested very low rates of acute rectal toxicity ([@B22]--[@B24]). However, such studies did not collect outcomes until 1 month after treatment. As a result of the short SBRT treatment course (1--2 weeks), acute symptoms develop near the end of treatment and last for only a few days, causing potential underestimation of the actual rates of acute morbidity when the assessment is made at one month. On the other hand, the length and burdensome nature of the EPIC-26 would preclude patients from filling out a daily questionnaire. A time point with a 7 day recall period was chosen for this study as providing a balance between the limits of elderly patients' memory and the burden of filling out time-consuming questionnaires. Thus, to the best of our knowledge, this is the first study to specifically address proctitis 1 week following the completion of prostate SBRT.

Indeed, our results demonstrate that overall acute rectal morbidity is near its maximum several days after the completion of SBRT, improves by 1 month, and returns to baseline by approximately 3 months. Here, we report that 23% of patients experienced ≥ grade 2 acute GI toxicity at 1 week, an incidence which is comparable to those reported for conventional fractionated radiation therapy ([@B9], [@B10]). However, even mild bowel toxicity can adversely affect quality of life ([@B31]). Therefore, we utilized the EPIC questionnaire as a sensitive QOL instrument to further assesses bowel quality of life ([@B32]--[@B34]). The temporal pattern seen in acute bowel QOL and toxicity following SBRT for prostate cancer demonstrated here is comparable to the pattern reported following conventionally fractionated radiotherapy ([@B34]--[@B36]). The bowel QOL score is at its lowest near the end of treatment, but quickly recovers to the approximate baseline level by 3 months after treatment. Specifically, in our series, most moderate to big problems were seen at 1 week after SBRT, with approximately 25% of patients reporting moderate to big problems with bowel urgency and/or frequency.

Our prior paper reported the prevalence, severity, and overall incidence of bowel frequency and urgency, rectal pain, and rectal bleeding at 1 month following SBRT ([@B24]). Because the recall period for the EPIC-26 is 1 month, it was assumed that the 1 month follow-up questionnaire captures bowel morbidity at 1 week. However, based on the results of the current study, it can be concluded that the 1 month questionnaire under-ascertained acute rectal symptoms. Future symptom management trials assessing the impact of interventions on acute bowel morbidity following SBRT should therefore consider including toxicity measurement at 1 week after SBRT.

Currently, there are limited approaches to manage radiation proctitis. Medical treatments such as antidiarrheals or steroid suppositories are commonly administered in response to symptoms with modest benefit ([@B16]). Unfortunately, these agents cannot be used as prophylaxis due to significant side effects such as anal irritation and constipation, highlighting the necessity for ongoing clinical research directed at symptom management. In the future, to increase the distance between the prostate and the rectum and thus reduce rectal radiation exposure, we plan to investigate the utilization of absorbable spacers in the context of prostate SBRT ([@B37]). Symptom control trials assessing the clinical value of these spacers should evaluate the impact of spacers on acute bowel morbidity 1 week following treatment.

Moreover, a reduction in acute bowel morbidity may improve long-term clinical outcomes. Following conventionally fractionated radiation therapy, non-healing acute proctitis has been shown to directly progress to chronic late bowel morbidity ([@B38]). It has been hypothesized that permanent damage occurs when a large area of rectal mucosa is injured and subsequently unable to fully repair ([@B39]). If true, reducing the incidence and severity of acute proctitis would lead to reduction of chronic rectal morbidity. The existence of such consequential late effects in the setting of SBRT has yet to be fully characterized. Longer follow-up of this cohort will better elucidate the impact of acute proctitis following SBRT on the incidence of late proctitis.

The present study has several identifiable limitations. In contrast to the paper questionnaires completed prior to each clinic visit, questionnaire completion at the 1 week time point was performed over the phone. Though unlikely, using varied methods of questionnaire completion may have altered the outcomes at 1 week with respect to other time points. It should be noted, however, that previous studies have successfully used third-party phone-survey facilities for collection of quality of life questionnaires in the setting of prostate cancer ([@B5]). In addition, the study population was derived from a single institution cohort. This can limit the generalizability of our results to the general population.

Conclusion {#S5}
==========

Following prostate SBRT, the incidence and severity of acute radiation proctitis are similar to those seen at the end of a course of conventionally fractionated radiation therapy. Acute radiation proctitis peaks the week following SBRT completion. Therefore, toxicity evaluation and questionnaire completion should be collected at 1 week after treatment. This data should aid in the design of future symptom management clinical trials.
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